Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Pulmonary Vascular Disease
In patients with severe tricuspid regurgitation, right ventricular failure and pulmonary hypertension, is there any role of pulmonary vasodilator therapy?
Related Questions
How do you approach a patient with PAH on intermediate to high dose of oral treprostinil, who presents with missed doses but is not in shock?
Are you more permissive of perioperative interruption of anticoagulation for VTE depending on the location and relative chronicity of the thrombus?
How do you plan to integrate sotatercept into the current treatment algorithm for PAH, particularly in patients who are stable on existing therapies?
What is the goal oxygen saturation for patients with COPD and pulmonary hypertension?
Would you continue or stop anticoagulation for a DVT/PE in a patient with active cancer who has completed 6 months of therapy?
Do you routinely evaluate for PE if a DVT is found?
How do you manage erythrocytosis secondary to sotatercept for patients with PAH?
How do you approach a patient with recurrent VTE who develops VTE again after reduction of apixaban to 2.5 mg bid?
What is your approach to follow up after embolization of pulmonary AVM in patients with HHT?
How do you counsel patients who are hesitant to try behavioral therapies for insomnia instead of starting a sleep medication?
